Abstract
To advance the field of early detection with blood‐based screening tests and for industry to be able to significantly contribute to progress, collaboration, transparency, and innovative health economic approaches are needed. To achieve this, gaps in the current versus ideal frameworks need to be addressed at the regulatory, reimbursement, and guidelines levels by adopting an integrative, system‐level thinking to bring these important technologies to market and to improve on cancer outcomes by finding more cancers at earlier stages.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
